Highlights Zai Lab Limited Hong Kong S.E.

Equities

9688

KYG9887T1168

Market Closed - Hong Kong S.E. Other stock markets 09:08:34 21/06/2024 BST			5-day change	1st Jan Change
13.74 ^HKD	-1.43%		-7.41%	-36.09%

06-20	Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme	MT
06-14	Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Tech, Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday	06-04	MT
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower	05-24	MT
Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise	05-22	MT
Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis	05-22	CI
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment	05-20	MT
Zai Lab and Innoviva Specialty Therapeutics Announces NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	05-20	CI
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading	05-16	MT
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator	05-14	MT
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy in China	05-14	CI
Asian Equities Traded in the US as American Depositary Receipts Begin Week Higher	05-13	MT
Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro	05-13	MT
Zai Lab's Cancer Drug Gets NDA Approval in China	05-13	MT
Zai Lab Limited Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China?s NMPA	05-13	CI
Zai Lab's Shares Rise After Q1 Beat	05-09	MT
Top Premarket Gainers	05-09	MT
Zai Lab Q1 Loss Widens Despite Higher Revenue	05-09	MT
Zai Lab Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading, End Week Over 2% Higher	05-03	MT
Bristol-Myers Squibb Therapy for Pretreated Non-Small Cell Lung Cancer Meets Primary Endpoint	04-01	MT
Zai Lab Reports Lesser Loss in 2023	03-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Zai Lab Limited Hong Kong S.E.

Equities

9688

KYG9887T1168

Highlights

Filters